TRIUMPH program overview The TRIUMPH clinical development program includes multiple large-scale trials designed to confirm the Phase 2 findings in broader, more diverse populations
The clinical case for long-term obesity pharmacotherapy has been strengthened by SELECT trial cardiovascular outcome data, growing insurance coverage mandates, and the demonstrated durability of weight loss maintenance in patients who remain on GLP-1 therapy
Realistic expectations are important
This substantial deacetylation is the reason that high plasma levels of acetyl-l-carnitine are not observed after its oral intake, unlike after parenteral administration, during which the substance bypasses the gut and enters the bloodstream directly
A significant interaction between group and time ( 2 (7) = 18.86, p = 0.009, f = 0.39) was found in the linear mixed effects model, revealing that the GLP-1RA group consistently rated their intoxication lower across multiple timepoints compared to the control group (Fig